Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254293 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT00254293 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 87 participants.
The verdict
NCT00254293, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.
Interventions
- DRUG Abatacept or Placebo (both as IV & SC Solution)
- DRUG Abatacept or Placebo (both as IV & SC solution)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254293
The ClinicalTrials.gov registry entry for NCT00254293 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abatacept or Placebo (both as IV & SC Solution) is the first listed.
NCT00254293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00254293 about?
NCT00254293 is a clinical study titled "Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)". The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.
What is the current status of trial NCT00254293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2006-01. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00254293?
The interventions under investigation include: Abatacept or Placebo (both as IV & SC Solution) (DRUG), Abatacept or Placebo (both as IV & SC solution) (DRUG).
Who is sponsoring clinical trial NCT00254293?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.